Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs National Beverage Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.42 (market cap $9.43B), while National Beverage Corp. trades at $30.62 (market cap $2.89B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.3× National Beverage Corp.'s market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| BIO | FIZZ | |
|---|---|---|
Market Cap | $9.43B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $46.75 |
52-Week Low | $241.71 | $30.53 |
Enterprise Value | $9.18B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
FIZZ trades at $30.60, down 1.42% on the day, with bearish technical signals dominating. The stock shows mixed fundamentals with strong profitability metrics including 37% gross margins and 34% ROE, but faces growth challenges as revenue has stagnated around $1.2B annually. Recent earnings have missed expectations in three of the last four quarters, while the company maintains dividend payments with a recent $3.25 special dividend declaration.
The outlook remains cautious given stalled revenue growth and bearish analyst sentiment with 50% sell ratings. While valuation appears reasonable at 15.7x P/E, competitive pressures in the sparkling water market and declining LaCroix volumes present significant headwinds. The stock's current technical weakness near support levels suggests continued pressure unless fundamental catalysts emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
